What FDA's new botanical drug products docket means for supplement brands

What exactly did FDA announce?

On September 4, 2026, FDA published a notice in the Federal Register opening a public docket, FDA-2026-N-9550, titled “Advancing Development of Botanical Drug Products; Request for Information.”

The notice is a request for information. FDA is not proposing a new rule or changing any regulation at this time. The agency states it wants to “better understand stakeholders’ perspectives on the state of BDP development in the United States, challenges encountered, and potential solutions to gathering the information required by the Federal Food, Drug, and Cosmetic Act (FD&C Act).”

The deadline for submitting comments is November 3, 2026. Comments can be filed electronically through regulations.gov or by mail to the Dockets Management Staff in Rockville, Maryland. Late comments will not be considered.

Is this about dietary supplements?

This notice is not about dietary supplements. FDA defines what it means by “botanical drug products” very precisely in the text: “drug products that include or may be derived from plant materials, algae, macroscopic fungi, or combinations thereof and that are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans.”

The notice references the drug definition in section 201(g)(1) of the FD&C Act. It also notes that BDPs come in forms including solutions, powders, tablets, capsules, tinctures, topicals, and injections. It does not mention dietary supplements, structure/function claims, or section 201(ff) of the FD&C Act, which defines dietary supplements.

If your product is a dietary supplement positioned for wellness or nutritional support, this docket does not directly regulate it. The document is silent on supplement-specific obligations under 21 CFR Part 111.

Then why should a supplement brand pay attention?

Many supplement brands sell botanical powders, capsules, or extracts. Where a product sits — drug or supplement — depends on its intended use as shown by claims, labeling, and marketing. FDA’s deeper exploration of botanical drug development often sharpens the agency's view of that boundary.

Input FDA gets on quality frameworks, batch-to-batch variability, and real-world evidence for BDPs can influence how the agency thinks about manufacturing controls and clinical substantiation more broadly. While the notice does not propose supplement standards, the conversation may surface expectations that ultimately affect how a document reviewer looks at a botanical supplement’s quality documentation.

The notice also reminds brand owners that four botanical drug products have been approved as prescription drugs via the NDA and BLA pathways, and that botanical active ingredients like psyllium and witch hazel can be marketed under OTC monographs. That underlines that the drug route for botanicals is real, and FDA is working to make it more accessible.

What topics is FDA asking about?

FDA lists three topic areas. Research and development experience questions ask what challenges stakeholders have encountered in botanical research or drug product development programs, how they use existing FDA resources, and what systems they have in place for gathering information required by the FD&C Act.

General challenges questions ask about scientific and economic challenges, and the differences between developing minimally purified or whole plant products versus highly purified isolates.

General opportunities questions ask what innovative approaches FDA or industry could take, what updates to guidance would add clarity, what standards development opportunities exist outside FDA, what study designs suit complex botanical mixtures, and how well-established use or real-world evidence could facilitate development.

The notice mentions the December 2016 guidance “Botanical Drug Development” as the current reference, and cites a recent roundtable where participants identified opportunities like incorporating real-world evidence and applying quality frameworks to address batch-to-batch variability.

What the notice does NOT say

The notice does not propose any changes to the dietary supplement regulatory framework. It does not mention 21 CFR Part 111, current Good Manufacturing Practices for supplements, or any requirement for supplement firms to file comments.

It does not introduce new labeling rules, testing mandates, or premarket notification requirements for supplements. It does not state that existing supplement ingredients will be reclassified.

The source text does not indicate how or when FDA will act on the comments received. There is no timeline for a subsequent proposed rule, guidance update, or policy announcement attached to this docket.

What should a brand with botanical products consider doing now?

We suggest reviewing your claims with fresh eyes. If your product contains botanicals and your labeling or Amazon listing uses words like “treats,” “cures,” “prevents,” or describes a disease condition, that language points toward the drug category. The supplement space only permits structure/function claims that do not claim disease treatment.

A sensible step is to pull every claim your brand makes on labels, detail pages, and advertising and check them against the drug definition in section 201(g)(1) of the FD&C Act. The notice does not change the definition, but the heightened agency attention on botanicals makes it a good moment to tighten your compliance.

If your brand is serious about developing a botanical drug product, the notice signals that FDA wants to hear about real-world development hurdles. Filing a comment by November 3, 2026 is a concrete way to shape future guidance. You may also consider looking at the four approved BDP examples mentioned — sinecatechins, crofelemer, birch triterpenes, and anacaulase-bcdb — to understand what a successful drug-quality botanical development program looks like.

How might this affect what a document reviewer looks for?

A document reviewer responsible for supplement compliance files won't see an immediate change from this notice. There is no new testing requirement, no updated specification sheet format, and no change to Amazon’s verification checklist.

Over time, if FDA’s request leads to refined thinking about quality characterization of complex botanicals, third-party reviewers and retailers may ask more pointed questions about identity testing and batch-to-batch consistency for botanical ingredients in supplements. The notice itself does not require this. It is worth observing where the standards conversation goes because quality expectations for supplements often follow the lead of the drug-side discussion, even when legally distinct.

Frequently asked questions

Does this notice mean my botanical supplement is now considered a drug?

No. The notice defines botanical drug products as those intended to diagnose, cure, mitigate, treat, or prevent disease. It does not reclassify any dietary supplement. Whether a product is a drug depends on its intended use as shown by claims and labeling, not on this docket.

When is the deadline to submit a comment?

Comments must be received by November 3, 2026. Electronic submissions through regulations.gov are accepted until 11:59 p.m. Eastern Time. Written submissions must arrive at the Dockets Management Staff by that date. Late comments will not be considered.

Does this change what I need to submit to Amazon for a botanical supplement listing?

No. The notice is a request for information, not a new regulatory requirement. It does not alter any Amazon supplement verification checklist or testing mandate. Your current obligation remains to provide whatever documentation your TIC provider or Amazon requires under existing policies.

What if my product is a botanical but I only make structure/function claims?

The notice does not discuss structure/function claims or the dietary supplement definition. If your product is labeled and marketed as a supplement without disease claims, this docket does not directly affect it today. The risk lies in claims that drift toward disease, which is a pre-existing line, not a new one.

What are the four approved botanical drugs FDA mentions?

FDA lists three NDAs with active ingredients sinecatechins, crofelemer, and birch triterpenes, and one BLA with anacaulase-bcdb. It also notes that botanicals like psyllium and witch hazel can be marketed under OTC monographs without an approved drug application if they meet applicable conditions.

Related guides

• Structure/function claims vs. disease claims: where's the line on a supplement label?
• What is an NDI notification, and when does a supplement need one?
• What is the '100 percent' identity testing rule under 21 CFR Part 111?